Documentation of Safety and Efficacy of Synagis in Preterm Infants.
Phase of Trial: Phase IV
Latest Information Update: 17 Aug 2016
At a glance
- Drugs Palivizumab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- Sponsors Abbott Laboratories; AbbVie
- 15 Aug 2016 Status changed from recruiting to completed.
- 19 May 2014 Planned end date changed from 1 May 2015 to 1 May 2017 as reported by ClinicalTrials.gov.
- 03 Jun 2013 Planned End Date changed from 1 Jun 2015 to 1 May 2015 as reported by ClinicalTrials.gov.